The Conversation (0)
Delivra released their financial results for their second quarter of the year.
Delivra (TSXV:DVA) released their financial results for their second quarter of the year.
As quoted in the press release:
“We delivered another solid quarter driven by increased sales of our flagship pain and nerve products and our team’s disciplined focus on cost efficiencies. With increased sales, strong margins, and a robust consumer and pharmaceutical portfolio, Delivra has built a platform to grow both our consumer and pharmaceutical businesses,” said Dr. Joseph Gabriele, CEO of Delivra. “We believe there is significant opportunity for further growth of our OTC portfolio in Canada and will continue to focus on driving revenue and optimizing profitability through strong marketing and advertising programs. Our proprietary transdermal platform provides an additional opportunity for revenue growth within our pharmaceutical portfolio, specifically for diabetic wound healing.”
Click here to read the full press release.
Source: www.marketwired.com